PB0758 - Comparative study of immunothrombotic biomarkers in patients with rheumatologic diseases and long COVID

Monday, June 26, 2023

18:30 – 19:30 ET

Room: Exhibition

Presenting Author(s)

Yesenia Ambriz-Murilo, 8536283

Rheumatologist
REGIONAL HOSPITAL OF ISSSTE, MORELIA, MEXICO
Morelia, Michoacan de Ocampo, Mexico

Co-Author(s)

Alan Cano Méndez, PhD (he/him/his)

Facultad de Ciencias Medicas y Biológicas "Dr. Ignacio Chávez". Universidad Michoacana de San Nicolás de Hidalgo
Morelia, Michoacan de Ocampo, Mexico
NG

Nallely García-Larragoiti

POST DOC
MICHOACAN UNIVERSITY OF SAN NICOLAS DE HIDALGO
MORELIA, Michoacan de Ocampo, Mexico
SL

Sandra Edith López-Castañeda

PROFESOR
MICHOACAN UNIVERSITY OF SAN NICOLAS DE HIDALGO
MORELIA, Michoacan de Ocampo, Mexico
PG

Patricia Guzmán-cancino

STUDENT OF MASTER IN SCIENCE
MICHOACAN UNIVERSITY OF SAN NICOLAS DE HIDALGO
MORELIA, Michoacan de Ocampo, Mexico
MT

Mercedes Trujillo

PREGRADE STUDENT
MICHOACAN UNIVERSITY OF SAN NICOLAS DE HIDALGO
MORELIA, Michoacan de Ocampo, Mexico
YJ

Yeny Jiménez-Vega

PREGRADE STUDENT
MICHOACAN UNIVERSITY OF SAN NICOLAS DE HIDALGO
MORELIA, Michoacan de Ocampo, Mexico
MV

Martha Eva Viveros-Sandoval

Professor
Facultad de Ciencias Medicas y Biológicas "Dr. Ignacio Chávez". Universidad Michoacana de San Nicolás de Hidalgo
Morelia, Michoacan de Ocampo, Mexico

Background: The persistence of symptoms after COVID-19 recovery has been defined as long COVID. It has been reported that SARS-CoV-2 infection is associated with a thromboinflammatory state, which may persist even after the resolution of the acute process. In patients with chronic inflammatory processes such as autoimmune diseases, the incidence of persistence is higher. It is unknown whether the active immunothrombotic state correlates with the presence of prolonged COVID.

Aims: The aim of this work was to correlate immunothrombotic alterations in patients with chronic inflammatory diseases and the persistence of long COVID.

Methods: A total of 42 patients who reported post-COVID-19 sequelae, agreed to participate and signed an informed consent form were included. Samples were classified into: Rheumatologic Diseases (RD), Metabolic Syndrome (MS), and Healthy Donors. Clinical and demographic data were registred. Whole human blood was obtained from patients by clean venipuncture. Plasma samples was obteined. The immunothrombotic biomarkers: D-Dimer (D-D), Tissue Factor (TF), Interleukin-6 (IL-6), and P-selectin (P-sel) were determined by flow cytometry using the Human Thrombosis Panel LegendPLEX. BIOLEGEND®).

Results: Differences in age and body mass index (BMI) between groups were found. A significant increase in plasmatic concentration of IL-6 in the MS group when compared to the control group (p < 0.01). There is an increase in the concentration of P-Sel in the RD group compared with healthy donors (p < 0.01). It is important to mention that all patients in the RD study group are under active treatment for their disease. When evaluating presumptive biomarkers of a procoagulant state, we found elevations in TF concentrations in the SM group when compared against the other study groups (p < 0.01). Finally, D-D concentrations was incresed in RD group.

Conclusion(s): Subjects with a chronic inflammatory state present increased concentrations of thrombotic inflammatory biomarkers that correlate with the persistence of symptoms in subjects recovered from COVID-19.